GlobeNewswire·Nov 9, 2026, 6:00 AM ET

Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan

Edesa Biotech & Kyorin Pharmaceutical entered an exclusive collaboration to develop & commercialize paridiprubart in Japan for ARDS treatment.
The deal includes a $12 million upfront payment plus potential milestones up to $134 million & double-digit royalties on net sales.
Kyorin will fund all development, regulatory, & commercialization activities in Japan while Edesa retains rights outside Japan.
Edesa will manufacture & supply the drug candidate while coordinating development activities with Kyorin.
Kyorin secured a right of first negotiation for acute kidney injury (AKI) & a non-exclusive right to negotiate other indications.
Phase 3 data showed paridiprubart reduced 28-day mortality by 39% versus 52% for placebo with a safety profile comparable to placebo.
Paridiprubart is a first-in-class monoclonal antibody targeting toll-like receptor 4 (TLR4) to modulate innate immune responses.
Edesa continues to hold other pipeline assets including EB06 for vitiligo & EB01 for allergic contact dermatitis.
Japan represents approximately 4 to 5 percent of global pharmaceutical spending & is a key market for this partnership.

Company: Edesa Biotech, Inc.
Keywords: Nasdaq:EDSA, Edesa Biotech, Inc., ARDS, Acute Kidney Injury, Biotech, Respiratory, Japan, License, EDSA